
	Where results make sense

Topic: Reboxetine

Related Topics

Tricyclic antidepressant

Venlafaxine

Paroxetine

Monoamine oxidase inhibitor

Clinical depression

Sertraline

Selective serotonin reuptake inhibitor

Fluoxetine

Serotonin

Alprazolam

PhyloCode

JD Salinger

Syrian rue

Burger King

Loyalty Day

	Reboxetine - Wikipedia, the free encyclopedia
		Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD.
		Both the (R,R)-(-) and (S,S)-(+)-enantiomers of reboxetine are predominantly metabolized by the CYP3A4 isoenzyme.
		According to Weiss et al, reboxetine is an intermediate-level inhibitor of P-glycoprotein, which gives it the potential to interact with ciclosporin, tacrolimus, paroxetine, sertraline, quinidine, fluoxetine, fluvoxamine.
	en.wikipedia.org /wiki/Reboxetine (488 words)

	Anxiety Zone - Reboxetine
		Reboxetine is currently marketed by Pharmacia and Upjohn.
		By mid-2001, reboxetine was licensed worldwide in over 50 countries, including Italy, Germany and the UK.
		Reboxetine has a relatively short elimination half life of 12.5 hours and therefore is often given twice daily.
	www.anxietyzone.com /drugs/reboxetine.html (209 words)

	DAVEDAX: Manufacturer's Insert: Approved Uses
		Reboxetine is indicated in the acute treatment of depression/major depression and for maintaining the clinical improvement in patients initially responding to treatment.
		As Reboxetine has not been tested in patients with convulsive disorders in clinical studies and since rare cases of seizures have been reported in clinical studies, it should be given under close supervision to subjects with a history of convulsive disorders and it must be discontinued if the patient develops seizures.
		In vitro studies on metabolism indicate that Reboxetine is metabolised primarily by the isoenzyme CYP3A4 of cytochrome P450; Reboxetine is not metabolised by CYP2D6.
	www.antiaging-systems.com /apruses/davedax.htm (1675 words)

	Data Sheet
		Reboxetine is devoid of in vitro binding to either alpha 1 or alpha 2 adrenoreceptors, however a functional interference with alpha-adrenoreceptors at high doses in vivo cannot be excluded.
		The renal clearance of reboxetine is excreted unchanged in urine.
		Reboxetine should be used with caution in patients whose underlying medical conditions might be compromised by increases in heart rate, eg, patients with hyperthyroidism, heart failure, or recent myocardial infarction.
	www.medsafe.govt.nz /profs/Datasheet/e/Edronaxtab.htm (4576 words)

	Reboxetine efficacy and tolerability
		Reboxetine is a unique selective norepinephrine reuptake inhibitor (NRI) with proven antidepressant efficacy in pharmacologic and biochemical tests predictive of antidepressant properties.
		Four hundred forty-nine patients with a diagnosis of either major depressive disorder or dysthymia were treated with reboxetine in these clinical studies of 4 weeks' to 12 months' duration.
		Reboxetine was well tolerated; adverse events reported were mainly mild to moderate in severity, and there were no clinically significant changes in vital signs or laboratory parameters.
	www.reboxetine.org /reboxetine/reboxetine-review.htm (244 words)

	Reboxetine Effective In Treating Depression Symptoms (Site not responding. Last check: 2007-11-03)
		The efficacy and tolerability of reboxetine was evaluated in two double-blind, parallel-group, randomised multi-centre studies of 549 patients in Europe, Latin America and Australia, diagnosed with major depression.
		Reboxetine was well-tolerated in both studies, with an overall adverse event rate similar to fluoxetine: 67 percent for reboxetine, 65 percent for fluoxetine.
		Reboxetine works by selectively inhibiting a process in the brain called reuptake increasing the norepinephrine supply and its neurotransmission to various sections of the brain.
	www.pslgroup.com /dg/fe50e.htm (726 words)

	Reboxetine.
		Reboxetine pharmacokinetic parameters, calculated after the single dose using non-compartmental analysis, were in good agreement with those obtained in previous studies.
		Reboxetine is a novel antidepressant that has been shown to be effective in the treatment of major depressive disorders.
		The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4, and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed therapeutic tablet formulation (4 mg).
	www.psycom.net /depression.central.reboxetine.html (1877 words)

	TREATMENTS FOR DEPRESSION - Reboxetine
		Reboxetine is used to improve mood in people who are feeling low or depressed.
		Reboxetine is used to help the symptoms of anxiety and a number of other symptoms.
		Reboxetine is not addictive, but if you have taken an antidepressant for eight weeks or more you may experience some mild "discontinuation" effects if you stop it suddenly (although this is very, very rare with reboxetine).
	www.nmhct.nhs.uk /pharmacy/reboxetine.htm (2073 words)

	Reboxetine
		Although reboxetine may be approved as a new anti-depressant in the U.S., the first published study of its use in man in 1991 mentions it as an anti-depressant.
		Reboxetine = Fluoxetine in DB: A large 381 patient 8-week DB PC trial of reboxetine vs. fluoxetine vs. placebo found that both anti-depressants had significantly higher response rates than the placebo, but did not differ from each other despite the fact that their known mechanisms of action are exactly the opposite, i.e.
		Reboxetine but not Paroxetine Improved Cognitive Functioning in Depressed in DB: In a small DB PC study of 74 MDD patients, University of Utah researchers documented that at the end of 8 weeks, the cognitive functioning of patients on reboxetine 8-10 mg/d improved but that the cognitive functioning on paroxetine patients did not.
	www.modern-psychiatry.com /reboxetine.htm (3016 words)

	Pharmaceutical Technology - Nanjing Depont Pharmachem - Reboxetine, Sesamin, Soy Isoflavone, Buckwheat and Hoodia
		Reboxetine is a NorAdrenaline Reuptake Inhibitor (NARI) that is approved in over 50 countries as an anti-depressant.
		Reboxetine is being used for the long-term and short-term treatments for depression and has been developed as a first-line therapy for major depressive disorders.
		Reboxetine is used to improve mood in people who are feeling low or depressed and to help people combat the symptoms of anxiety.
	www.pharmaceutical-technology.com /contractors/materials/nanjing (702 words)

	American College of Medical Toxicology
		Reboxetine is a novel, selective norepinephrine reuptake inhibitor (NRI) that provides a new therapeutic alternative and, perhaps, advance for the treatment of depression.
		Therefore, while an overdose of reboxetine or an SSRI alone may not result in severe toxicity, the combination may. In general, since reboxetine does not itself potentiate serotonin neurotransmission, it is not expected to precipitate the serotonin syndrome when combined with agents that increase CNS serotonin levels.
		Reboxetine is primarily metabolized by CYP 3A4 and its clearance may be significantly increased and decreased by inducers and inhibitors of this enzyme, respectively.
	www.ijmt.net /ijmt/3_4/3_4_26.html (3149 words)

	Reboxetine: A guide to Reboxetine drug
		Reboxetine is an antidepressant known as a selective noradrenaline re-uptake inhibitor.
		Reboxetine is indicated for the treatment of depressive illness and for maintaining the clinical improvement in patients initially responding to treatment.
		Since rare cases of seizures have been reported in clinical studies, reboxetine should be given under close supervision to subjects with a history of convulsive disorders and it should be discontinued if the patient develops seizures.
	www.depression-guide.com /reboxetine.htm (648 words)

	Latest Breaking Health News & Information: Applesforhealth.com
		Reboxetine, a selective norepinephrine reuptake inhibitor awaiting Food and Drug Administration approval, is equal to or better than Prozac for some forms of depression, researchers reported at the annual meeting of the American Psychiatric Association in Washington.
		Reboxetine is the first of the new class of norepinephrine drugs believed to be far safer than the older drugs.
		"Reboxetine is more effective that fluoxetine (Prozac) in improving social functioning in depressed patients and produces a better quality of remission," said Dr. Hans-Jurgen Moller of the department of psychiatry at the University of Munich.
	www.applesforhealth.com /deprdrug1.html (709 words)

	REBOXETINE
		Reboxetine is an anti-depressant with a unique group of actions that tackle anxiety and stimulate the mind
		Reboxetine is an anti-depressant known as a selective noradrenaline re-uptake inhibitor (SNRI).
		In studies with narcolepsy (uncontrolled daytime sleeping) Reboxetine was noted to exert stimulant and anticataplectic effects.
	www.antiaging-systems.com /a2z/reboxetine.htm (415 words)

	Effects of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Norepinephrine and Serotonin Transmission in ...
		The net effect of long-term reboxetine treatment on 5-HT transmission was determined by stimulating the ascending 5-HT pathway at a frequency (1 Hz) similar to the spontaneous firing rate of 5-HT neurons (Vandermaelen and Aghajanian 1983).
		In contrast, reboxetine injections did not alter this parameter for 5-HT applications on the same neurons, demonstrating that acute injections of reboxetine do not impact upon the function of the 5-HT transporter in this postsynaptic structure when the effect of NE is prolonged more than 2-fold (Figures 1 and 3).
		Since both the acute and long-term administration of reboxetine produced the same degree of enhancement of NE in the extracellular milieu in the same experiments in the hippocampus, the relationship between the delayed clinical response to reboxetine with respect to hippocampal function is not clear.
	www.nature.com /npp/journal/v25/n6/full/1395727a.html (7393 words)

	Reboxetine Beats Placebo for Severe Depression - Brief Article Family Pratice News - Find Articles
		Reboxetine was superior tQ placebo for the treatment of severe major depressive disorder in a double-blind study.
		Reboxetine is the first in a new class of drugs, called selective noradrenaline reuptake inhibitors.
		Previous studies have found that reboxetine is as effective as--and better tolerated than--the tricyclic antidepressants desipramine and imipramine in mixed populations of patients with mild to severe depression, the investigators said.
	www.findarticles.com /p/articles/mi_m0BJI/is_6_30/ai_63591424 (463 words)

	[No title] (Site not responding. Last check: 2007-11-03)
		Considering the comparative trials with reboxetine conducted in Europe (in which it is referred to as an NARI or noradrenaline reuptake inhibitor), it may well be promoted as superior for particular outcomes and for specific populations of patients with depression.
		In addition to the studies demonstrating that reboxetine antidepressant efficacy is superior to placebo and comparable to a TCA, a head-to-head and a placebo-controlled study were conducted to compare reboxetine to fluoxetine.
		Reboxetine's superiority was vigorously debated (Sackeim, 1996), however, as have the reasons for disparate findings between antidepressant trials conducted in Europe and in the United States (Ackenheil et al., 1996).
	www.psychiatrictimes.com /p980710.html (1294 words)

	Structurally Unrelated Drugs
		Reboxetine's side effects include dry mouth, constipation, insomnia, increased sweating, rapid heartbeat, vertigo, urinary hesitance or retention, and impotence (in patients treated with doses above 8 milligrams a day).
		There are no adequate and well-controlled studies in pregnant women, so reboxetine should be used only if the potential benefit to the mother justifies the potential risk to the fetus.
		Reboxetine is not recommended for women who are breast-feeding.
	www.webmd.com /content/Article/87/99353.htm?pagenumber=5 (601 words)

	Nuova pagina 1
		Reboxetine, a drug that has a selective noradrenergic effect, is the most selective drug available.
		Those patients who improved with reboxetine over six weeks maintained their gains over the long-term of the study, with an 87.8 percent response rate.
		Some suggest that there may be more rapid improvement in social function with regard to reboxetine than with other antidepressants and that there might be greater efficacy with reboxetine than with SSRIs in severe depression.
	www.ilneurologo.com /pr11.htm (867 words)

	DG DISPATCH - AAGP: Reboxetine Effective In Late-life Depression (Site not responding. Last check: 2007-11-03)
		There have been a few studies on the efficacy and safety of reboxetine on geriatric depression.The first was an open-label study in 1999, followed by a double-blind comparison with imipramine and a long-term continuation study conducted in individuals who had responded acutely to reboxetine for major depression.
		According to Dr. Borson, reboxetine is as effective an antidepressant in terms of responders, clinical global improvement and remission as the old standards, such as imipramine.
		In comparison with imipramine in a double-blind, randomized, controlled trial, there were fewer dropouts with reboxetine than with imipramine.
	www.pslgroup.com /dg/1900b6.htm (929 words)

	Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats -- Rauhut et al. 303 (2): 664 -- Journal of ... (Site not responding. Last check: 2007-11-03)
		Reboxetine (a racemic mixture of R,R- and S,S-([2-[
		Berzewdski H, Van Moffaert M and Gagiano CA (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive disorder.
		Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A and Leonard BE (1999) Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
	jpet.aspetjournals.org /cgi/content/full/303/2/664 (6368 words)

	Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors -- Miller et al. 302 ... (Site not responding. Last check: 2007-11-03)
		Data from the 60-min period of reboxetine and nicotine superfusion are presented in Fig.
		Reboxetine was included in the superfusion buffer for 30 min before the addition of nicotine to the buffer, and superfusion continued for an additional 60 min.
		H overflow during the 60-min period of exposure to nicotine in the absence or presence of reboxetine.
	jpet.aspetjournals.org /cgi/content/full/302/2/687 (5217 words)

	Reboxetine or MAOI's?
		Today I am really not looking forward to the diet restrictions of an MAOI and was wondering if it would be better to try the Reboxetine first before trying the MAOI again with treatment of hypotension if needed.
		Consideration should also be given to treatment with Electroconvulsive therapy (ECT), which is a often a safe and effective treatment for medication-resistant depression.
		Reboxetine is an antidepressant that is not approved by the Food & Drug Administration (FDA).
	www.medhelp.org /forums/mentalhealth/messages/30278.html (662 words)

	Reboxetine depression research
		Reboxetine is a NorAdrenaline Reuptake Inhibitor (NARI) that is approved in over 50 countries as an antidepressant.
		In May 2001, the FDA declined the approval of reboxetine for the US.
		It is helpful for anxiety and depression, especially with cerebral vascular disorder with mood symptoms and/or confusion continue
	www.reboxetine.org (79 words)

	Norepinephrine Transporter Function and Autonomic Control of Metabolism -- Boschmann et al. 87 (11): 5130 -- Journal of ... (Site not responding. Last check: 2007-11-03)
		Changes in energy expenditure and RQ during systemic infusion with increasing doses of isoproterenol in the presence of either reboxetine or placebo.
		The response was similar with placebo and with reboxetine.
		The slight increase in interstitial lactate with reboxetine
	jcem.endojournals.org /cgi/content/full/87/11/5130 (3222 words)

Try your search on: Qwika (all wikis)